Uveal melanoma is the most common primary tumor of the adult eye, with an incidence of 2 to 8 cases per million per year.
1 Despite excellent rates of local control of the primary tumor, the survival rate of patients with uveal melanoma is not good, with a mortality rate of up to 50%.
1 Indeed, metastatic spread to the liver, the preferential site of metastasis,
2 is followed by death for 80% of the patients within 1 year.
3 Although there is no standard of care for patients with metastatic disease, new targeted therapies are presently under investigation,
4 and local therapy of the liver seems to significantly improve survival, in the presence of a limited number of metastatic lesions.
5,6 However, current screening methods, including liver function tests and ultrasonography, do not identify metastases until the tumor burden is already large, with widespread development of liver metastases. Some liver function test results,
7,8 an increase in serum levels of S100,
9,10 tissue polypeptide-specific antigen,
11 growth differentiation factor 15,
12 osteopontin,
13,14 melanoma inhibitory antigen,
15 vascular endothelial growth factor,
14,16 and DJ-1,
17,18 and a decrease in serum levels of insulinlike growth factor 1
19 have been correlated with the development of metastasis. However, there is still a need for a good biomarker that indicates the presence of early metastasis of uveal melanoma.